Alife Health, a leading fertility technology company specializing in AI tools for in vitro fertilization (IVF), has announced a strategic partnership with Boston IVF, a prominent fertility clinic with over 25 locations across the U.S. The collaboration aims to implement the country’s first AI tool for IVF medication optimization, with the objective of enhancing patient outcomes through data-driven decisions.
The collaboration between Alife Health and Boston IVF is dedicated to optimizing IVF cycles through data-driven insights, signifying a convergence of advanced AI technology and extensive experience in reproductive medicine. By utilizing sophisticated machine learning algorithms, the partners aim to refine IVF treatment protocols, ultimately enhancing success rates for individuals undergoing assisted reproductive technologies.
“Our partnership with Alife marks a major milestone in the advancement of AI technology for fertility treatment,” says David Stern, CEO of Boston IVF. “At Boston IVF, we are always looking for new cutting-edge technologies to research, test, and integrate into our practices to provide the best possible care for our patients. By exploring the potential that AI technology can bring to our field, we aim to establish a new standard for IVF and continue to bring hope to millions of couples struggling with infertility.”
At the core of this collaboration lies Alife’s Stim Assist software, designed to optimize IVF medication protocols based on comprehensive data analysis. Drawing upon extensive datasets from thousands of historical IVF patient cycles, the software enables clinicians to tailor treatment plans that maximize egg yield while minimizing medication costs.
“Boston IVF, with its extensive network of fertility clinics and a long-standing reputation for excellence in reproductive medicine, was a natural choice for this collaboration,” says Paxton Maeder-York, CEO and founder of Alife. “Our past research has shown that using our Stim Assist software has produced improvements in both patient egg yield and cost savings. We couldn’t be more excited to partner with this storied institution as we pilot this software to demonstrate the immense promise that AI presents for the IVF industry.”
